PUBLISHER: The Business Research Company | PRODUCT CODE: 1942539
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942539
Cell counting refers to a range of techniques utilized for quantifying cells in the life sciences, facilitating diagnosis and treatment in various applications. These techniques are crucial for monitoring cell health and proliferation rates, assessing factors like immortalization or transformation, transfection or infection, seeding cells for subsequent experiments, and preparing for cell-based assays.
The primary consumables and accessories employed in cell counting include media, sera, and reagents, assay kits, microplates, accessories, and other related materials. Media, sera, and reagents play a vital role in cell culture, finding applications in areas such as cancer research, the development of biopharmaceuticals, regenerative medicine, and other research endeavors. Various products used in cell counting include spectrophotometers, single-mode and multi-mode readers, cell counters (including automated and manual variants), hemocytometers, flow cytometers, and hematology analyzers. Cell counting is widely utilized in research applications, clinical and diagnostic settings, as well as industrial applications. End-users of cell counting technologies include hospitals and diagnostic facilities, research institutions, pharmaceutical and biotechnology companies, among others.
Tariffs are impacting the cell counting market by increasing costs of imported optical components, sensors, microfluidic systems, reagents, and analytical instruments. Research institutions and pharmaceutical companies in North America and Europe are most affected due to reliance on imported laboratory equipment, while Asia-Pacific faces cost pressure on instrument exports. These tariffs are raising equipment acquisition costs and delaying lab upgrades. However, they are also supporting local instrument assembly, regional reagent production, and domestic innovation in laboratory automation technologies.
The cell counting market research report is one of a series of new reports from The Business Research Company that provides cell counting market statistics, including cell counting industry global market size, regional shares, competitors with a cell counting market share, detailed cell counting market segments, market trends and opportunities, and any further data you may need to thrive in the cell counting industry. This cell counting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cell counting market size has grown strongly in recent years. It will grow from $11.39 billion in 2025 to $12.49 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to expansion of life sciences research activities, growing use of cell culture techniques, rising pharmaceutical research investments, increased academic research funding, wider adoption of laboratory automation.
The cell counting market size is expected to see strong growth in the next few years. It will grow to $17.83 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for cell-based therapies, rising adoption of precision diagnostics, expansion of biotechnology research pipelines, growing use of ai-enabled laboratory analytics, increasing focus on standardized laboratory workflows. Major trends in the forecast period include increasing adoption of automated cell counting systems, rising use of flow cytometry-based cell analysis, growing demand for high-throughput cell counting, expansion of cell-based research applications, enhanced focus on data accuracy and reproducibility.
The increasing prevalence of chronic diseases is expected to drive the growth of the cell counting market in the coming years. Chronic diseases are defined as conditions that persist for a year or longer and require ongoing medical care, interfere with daily activities, or both. These diseases typically involve complex causes, multiple risk factors, long incubation periods, prolonged illness, and reduced functional capacity or impairment. Cell counting serves as a critical diagnostic, monitoring, and therapeutic tool for managing chronic illnesses. It enables healthcare professionals to detect and track changes in cell counts, providing valuable insights into disease progression and treatment efficacy. For example, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels not high enough to be classified as diabetes) in 2023, representing an 18% increase from 3,065,825 cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the cell counting market.
Leading companies in the cell counting market are strategically focusing on introducing innovative products to cater to the evolving needs of their consumer base. One notable example is the BD FACSDiscover S8 spectral cell sorter, developed by Becton, Dickinson, and Company (BD), a prominent U.S.-based medical device manufacturer. This innovative product utilizes spectral flow cytometry and high-speed imaging technologies, enabling the sorting of cells based on their visual properties. In contrast to traditional flow cytometry, which detects specific fluorescent bands, spectral flow cytometry collects the entire spectrum of signals produced by sample arrangements. This allows for multi-parameter sorting, offering researchers a more comprehensive understanding of cells. The BD FACSDiscover S8 Cell Sorter, launched in May 2023, incorporates game-changing technologies, including BD CellView Image Technology, enabling researchers to examine detailed microscopic images of individual cells and sort them rapidly based on visual criteria. Additionally, BD SpectralFX Technology facilitates high-parameter studies with full-spectrum cell sorting, enhancing performance through a flexible optical architecture and system-aware algorithms. These advancements significantly broaden researchers' capabilities, potentially revolutionizing research and the development of cell-based therapies in areas such as drug discovery, immuno-oncology, and genomics.
In August 2023, Cell Microsystems, a biotechnology company based in the U.S., acquired Fluxion Biosciences, Inc. for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in single-cell analysis and precision medicine by incorporating Fluxion Biosciences' innovative microfluidic technology and expertise in cellular analysis. Fluxion Biosciences, Inc. is also a U.S.-based biotechnology company.
Major companies operating in the cell counting market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Olympus Corporation, HORIBA Ltd., Logos Biosystems Inc., Becton Dickinson and Company, GE Healthcare, Agilent Technologies Inc., BioTek Instruments Inc., DeNovix Inc., Sysmex Corporation, Nexcelom Bioscience LLC, Beckman Coulter Inc., Roche Diagnostics International Ltd., Miltenyi Biotec GmbH, AccuBioTech Co. Ltd., ChemoMetec A/S, Countstar Microscopy Systems, Luminex Corporation, NanoEnTek Inc., Partec GmbH, Advanced Instruments Inc., Analytik Jena AG, Integra Biosciences AG, Meridian Bioscience Inc., Promega Corporation, Sartorius AG
North America was the largest region in the cell counting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell counting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cell counting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cell counting market includes revenues earned by entities by direct total, indirect total, direct differential, and indirect differential cell counting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cell Counting Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cell counting market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cell counting ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell counting market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.